A

s experimental drugs continue to fail in Alzheimer’s patients, research interest has increasingly shifted to finding a way to stop the disease long before it erodes people’s cognitive abilities.

But how do you identify the right people to target?

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories